Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Keiretsu Forum and MDB Capital Close 2025 With High-Impact Investor Summits, and Announces Expanded Summit Series for 2026
MDB Capital Holdings Provides Third Quarter 2025 Update
MDB Capital Holdings to Host Third Quarter 2025 Update Conference Call on Thursday November 20, 2025, at 4:30 p.m. Eastern Time
New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $133B Cardiac Diagnostics Market
MDB Capital Holdings, LLC to Present at the LD Micro Main Event XIX
LD Micro Celebrates the 2,000th Company: MDB Capital Holdings (MDBH)
PatentVest Welcomes Dr. Sarah Cork as Senior Patent Attorney, Expanding Life Sciences IP Leadership
MDB Capital Holdings Provides Second Quarter 2025 Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.